EuroPCR

PCR is a European organization dedicated to education and information in the field of interventional cardiology and minimally invasive transcatheter procedures. Its activities cover a large spectrum, from the organization of annual courses in Europe, Asia, the Middle East and Africa, to editing a scientific journal, publishing textbooks as well as providing training seminars on thematic subjects. For more information, visit https://www.pcronline.com/Courses/EuroPCR.

EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes
Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris.
Redo TAVR appears feasible for most patients with supra-annular, self-expanding Evolut valves
Researchers evaluated data from more than 200 patients who underwent redo TAVR, noting that women and patients with a higher BMI faced a higher risk of coronary flow compromise.
New self-expanding TAVR valve shows promise
It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device.
Boston Scientific's new TAVR system associated with high success rate, low mortality rate
The new-look device gained CE mark approval in Europe in 2020, but it has not been approved yet in the United States.
Medtronic’s newest self-expanding TAVR system linked to improved performance
Medtronic presented the real-world data at the PCR London Valves 2022 conference. The company's Evolut FX TAVR system gained FDA approval back in August 2021.

EuroPCR 2023: Late-breaking research examines the latest in TEER, TAVR and PCI outcomes

Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris.

May 17, 2023

The Medtronic Evolut TAVR valve on display at ACC.22.

Redo TAVR appears feasible for most patients with supra-annular, self-expanding Evolut valves

Researchers evaluated data from more than 200 patients who underwent redo TAVR, noting that women and patients with a higher BMI faced a higher risk of coronary flow compromise.

April 20, 2023

A team in China treated 10 patients—split evenly between men and women—with the SinoCrown TAVR valve developed by Lepu Medical Technology Company. The average patient age was 77.5 years old.

New self-expanding TAVR valve shows promise

It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device.

January 25, 2023

Boston Scientific's new TAVR system associated with high success rate, low mortality rate

The new-look device gained CE mark approval in Europe in 2020, but it has not been approved yet in the United States.

December 1, 2022

Medtronic launches Evolut FX TAVR system aortic stenosis.

Medtronic’s newest self-expanding TAVR system linked to improved performance

Medtronic presented the real-world data at the PCR London Valves 2022 conference. The company's Evolut FX TAVR system gained FDA approval back in August 2021.

November 29, 2022

Edwards Lifesciences Corporation has shared new one-year data on the safety and effectiveness of its Evoque transcatheter tricuspid valve replacement (TTVR) system among patients with tricuspid regurgitation (TR)

Edwards shares new one-year data on transcatheter tricuspid valve replacement

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates.

November 28, 2022

Transcatheter aortic valve replacement (TAVR) patients continue to benefit from an optimized pre- and post-procedural treatment strategy that utilizes the cusp overlap technique and the Evolut Pro and Pro+ TAVR valves, according to new findings presented at EuroPCR 2022 in Paris.

Cusp overlap technique, optimized treatment strategy tied to significant improvements for TAVR patients

The research, presented at EuroPCR 2022 in Paris, represented an updated look at the Optimize PRO study, an ongoing analysis of patients treated with Medtronic’s self-expanding Evolut Pro and Pro+ TAVR systems.

May 20, 2022

New data on cardiac damage before and after AVR suggests earlier treatment may be beneficial

Patients with higher levels of extravalvular cardiac damage prior to TAVR or SAVR face a higher risk of dying within two years, according to new findings presented at EuroPCR 2022 in Paris.

May 19, 2022

Around the web

Health Exec

Surgeons successfully transplant pig hearts into recently deceased humans

Surgeons at NYU Langone Health successfully transplanted two genetically engineered pigs hearts into recently deceased humans in June and July.

Health Exec

Machine learning predicts drug cardiotoxicity

Machine learning is playing a key role in predicting all major forms of drug cardiotoxicity, potentially helping reduce late-stage clinical trial failures.

Health Exec

After heart attack, older patients have longer hospital stays but smaller total bills

Heart attack patients aged 65 and up stay hospitalized longer than those aged 65 or under—yet the seniors ring up significantly smaller bills per stay. The bad news is that the “savings” likely come in the form of fewer percutaneous coronary interventions (PCIs, aka angioplasties) to open blocked heart arteries nonsurgically.